Showing 3,161 - 3,180 results of 9,456 for search 'significant ((((((greater decrease) OR (we decrease))) OR (nn decrease))) OR (mean decrease))', query time: 0.56s Refine Results
  1. 3161
  2. 3162
  3. 3163
  4. 3164
  5. 3165

    Vps34 orchestrates transcriptional and epigenetic remodeling events corresponding to terminal eTreg differentiation during perinatal life. by Erienne G. Norton (9612079)

    Published 2025
    “…See also <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#pbio.3003074.s017" target="_blank">S9 Table</a>. Data are shown as mean ± s.e.m. (<b>D</b>). Wilcoxon rank-sum test (<b>A</b>, <b>B</b>; <b>J</b>, right), Benjamini–Hochbert test (<b>C</b>), two-tailed Student <i>t</i> test (<b>D</b>, <b>I</b>), Fisher’s exact test (<b>F</b>–<b>H</b>), or bionomial test (<b>J</b>, left); NS, not significant. …”
  6. 3166
  7. 3167
  8. 3168
  9. 3169
  10. 3170
  11. 3171
  12. 3172
  13. 3173
  14. 3174

    Summary of related studies. by Most. Fatematuz Zohora (19429152)

    Published 2024
    “…To address these challenges, we propose the Dynamic Banker’s Deadlock Avoidance Algorithm (DBDAA). …”
  15. 3175

    Time complexity of different safety algorithms. by Most. Fatematuz Zohora (19429152)

    Published 2024
    “…To address these challenges, we propose the Dynamic Banker’s Deadlock Avoidance Algorithm (DBDAA). …”
  16. 3176

    Process execution halted due to deadlock. by Most. Fatematuz Zohora (19429152)

    Published 2024
    “…To address these challenges, we propose the Dynamic Banker’s Deadlock Avoidance Algorithm (DBDAA). …”
  17. 3177

    Novel Small-Molecule miR-124 Inducer Acts as “a Physiological Brake” of Inflammation in Ulcerative Colitis by Targeting the PIK3R2/PI3K/Akt Axis by Tiantian Wang (1688881)

    Published 2025
    “…This study identified FHND5032, a novel small-molecule miR-124 inducer, as a potent therapeutic candidate for UC. We found that FHND5032 significantly upregulated miR-124 expression in macrophages, surpassing the clinical-stage comparator ABX464 in vitro and in vivo. …”
  18. 3178

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  19. 3179

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  20. 3180

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”